Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEPW – Get Free Report) saw a significant decrease in short interest in the month of January. As of January 30th, there was short interest totaling 4,007 shares, a decrease of 74.5% from the January 15th total of 15,707 shares. Based on an average daily trading volume, of 16,755 shares, the short-interest ratio is presently 0.2 days. Based on an average daily trading volume, of 16,755 shares, the short-interest ratio is presently 0.2 days.
Coeptis Therapeutics Stock Down 12.9%
Coeptis Therapeutics stock traded down $0.00 during midday trading on Wednesday, reaching $0.01. The stock had a trading volume of 3,912 shares, compared to its average volume of 20,519. The firm’s fifty day simple moving average is $0.01 and its 200-day simple moving average is $0.02. Coeptis Therapeutics has a 1-year low of $0.00 and a 1-year high of $0.05.
About Coeptis Therapeutics
Coeptis Therapeutics is a clinical‐stage biopharmaceutical company focused on developing novel therapies for neurodegenerative and neuroinflammatory disorders. The company’s proprietary platform is based on engineered analogs of small heat shock proteins designed to modulate cellular stress responses, reduce inflammation and protect neurons from degeneration. Coeptis’s lead program is being advanced in amyotrophic lateral sclerosis (ALS), with additional preclinical studies underway in conditions such as multiple sclerosis and other central nervous system diseases.
Using its heat shock protein analog technology, Coeptis seeks to address the underlying pathology of neurodegeneration rather than merely managing symptoms.
Recommended Stories
- Five stocks we like better than Coeptis Therapeutics
- Nvidia CEO Issues Bold Tesla Call
- Your Bank Account Is No Longer Safe
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- The day the gold market broke
Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
